Jefferies Financial Group comments on third quarter 2021 results of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) – Investment analysts at Jefferies Financial Group released their 2021 third quarter earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research report released on Wednesday, October 6. Jefferies Financial Group analyst A. Tewari expects the biotech company to post earnings per share of ($ 0.14) for the quarter. Jefferies Financial Group currently has a “Buy” rating and a price target of $ 112.00 on the security. Jefferies Financial Group also released estimates for BioMarin Pharmaceutical’s Q4 2021 earnings at ($ 0.21) EPS, FY2021 earnings at $ 0.14 EPS, Q1 2022 earnings at $ 0.03 EPS. , Q2 2022 earnings at $ 0.07 EPS, Q3 2022 earnings at $ 0.12 EPS, Q4 2022 earnings at $ 0.19 EPS, and year 2022 earnings at $ 0.39 EPS.
Other analysts have also recently published research reports on the stock. Piper Sandler raised its price target for BioMarin Pharmaceutical shares from $ 112.00 to $ 119.00 and assigned the company an “overweight” rating in a report released Thursday, July 29. SVB Leerink reaffirmed a “buy” note on shares of BioMarin Pharmaceutical in a report released on Tuesday, September 14. The Royal Bank of Canada reiterated a “hold” note and issued a price target of $ 88.00 on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 7. Stifel Nicolaus Upgraded BioMarin Pharmaceutical Shares From A “Hold” Note To A “Buy” Note And Raised His Price Target For The Company From $ 86.00 To $ 96.00 In A Research Note Thursday, September 9. Finally, Zacks Investment Research downgraded BioMarin Pharmaceutical’s shares from a “buy” rating to a “hold” rating and set a price target of $ 81.00 for the stock. in a research note on Tuesday August 3. Three research analysts rated the stock with a conservation rating and nine gave the stock a buy rating. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has an average “Buy” rating and a consensus price target of $ 101.39.
NASDAQ: BMRN shares opened at $ 77.83 on Monday. The company’s 50-day mobile average price is $ 78.17 and its 200-day mobile average price is $ 78.90. The stock has a market cap of $ 14.27 billion, a price / earnings ratio of 18.14, a price / earnings-growth ratio of 15.81, and a beta of 0.53. BioMarin Pharmaceutical has a 52 week low at $ 71.65 and a 52 week high of $ 92.57. The company has a quick ratio of 3.71, a current ratio of 5.32 and a debt ratio of 0.25. BioMarin Pharmaceutical (NASDAQ: BMRN) last released its results on Tuesday, July 27. The biotech company reported earnings per share of $ 0.07 for the quarter, beating Thomson Reuters consensus estimate by $ 0.18 ($ 0.11). The company posted revenue of $ 501.69 million for the quarter, compared to $ 448.84 million expected by analysts. BioMarin Pharmaceutical had a net margin of 43.68% and a return on equity of 3.34%.
Several institutional investors and hedge funds have recently changed their positions in the company. Inspirion Wealth Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 10.9% during the third quarter. Inspirion Wealth Advisors LLC now owns 5,655 shares of the biotech company valued at $ 437,000 after acquiring an additional 557 shares in the last quarter. Veriti Management LLC increased its position in BioMarin Pharmaceutical by 29.6% in the 3rd quarter. Veriti Management LLC now owns 3,828 shares of the biotech company valued at $ 296,000 after purchasing 874 additional shares in the last quarter. Berman Capital Advisors LLC strengthened its position in BioMarin Pharmaceutical by 59.2% in the 3rd quarter. Berman Capital Advisors LLC now owns 936 shares of the biotech company valued at $ 71,000 after purchasing 348 more shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in BioMarin Pharmaceutical by 1,315.8% in the second quarter. Newbridge Financial Services Group Inc. now owns 538 shares of the biotech company valued at $ 45,000 after purchasing an additional 500 shares in the last quarter. Finally, Parametric Portfolio Associates LLC strengthened its position in BioMarin Pharmaceutical by 1.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 213,604 shares of the biotech company valued at $ 17,823,000 after purchasing an additional 3,347 shares in the last quarter. Institutional investors and hedge funds hold 94.44% of the company’s shares.
About BioMarin Pharmaceutique
BioMarin Pharmaceutical, Inc is committed to the development and commercialization of therapies for people with rare diseases and serious and life-threatening medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide and BMN 307. The company was founded by John C. Klock, Christopher M.
Recommended story: price target
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in BioMarin Pharmaceutical right now?
Before you consider BioMarin Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and BioMarin Pharmaceutical was not on the list.
Although BioMarin Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here